



CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for HFrEF

Panel Member's Relationships with Industry (RWI)

The CCS is committed to preserving the scientific integrity of its Guidelines and Position Statements through transparency and management of relationships with industry (RWI). Panel members must disclose all relationships with industry regardless of relevance to the statement topic (see below). When a potential conflict exists, the affected member must recuse during the formal consensus voting process. For more information on the CCS Guideline Development process, please visit www.ccs.ca.

Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this statement.

Member	Consulting Fees/ Honoraria	Clinical Trials	Other Financial Benefit	Relevance to Statement
Primary Panel				
Michael McDonald	Novartis, Servier	None	None	
Sean Virani	Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS/Pfizer Alliance, Medtronic, Merck, Novartis, Pfizer, Servier	Abbott, AstraZeneca, Boehringer Ingelheim, Medtronic, Novartis, Pfizer	None	
Eileen O'Meara	Amgen, American Regent, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Merck, Novartis	Amgen, Abbott, American Regent, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Eidos, Novartis, Merck, Sanofi	None	
Michael Chan	Novartis, Servier	Merck, Novartis	None	
Anique Ducharme	None	None	None	
Justin A. Ezekowitz	Bristol-Myers Squibb, Novartis, Pfizer, Servier	Amgen, Bayer, Bristol-Myers Squibb, Johnson & Johnson, Novartis, Merk, Trevena	None	
Nadia Giannetti	AstraZeneca, BMS/Pfizer Alliance, Medtronic, Novartis, Pfizer, Servier	Novartis, Servier	None	
George A. Heckman	None	None	None	
Jonathan G. Howlett	Abbot Vascular, AstraZeneca, Bayer, Boehringer Ingelheim, Medtronic, Merck, Novartis, Otsuka, Pfizer, Servier, St. Jude Medical	Amgen, AstraZeneca, Bayer, Johnson & Johnson, Medtronic, Novartis, Servier	None	
Sheri L. Koshman	None	None	None	
Serge Lepage	Novartis, Sanofi, Servier	Amgen, Merck, Novartis	None	
Lisa Mielniczuk	Actelion, Bayer, Pharmascience, Servier	Bayer	None	
Gordon W. Moe	Novartis, Otsuka, Pfizer	Merck, Novartis, Otsuka	None	
Elizabeth Swiggum	Boehringer Ingelheim, Novartis, Servier	Boehringer Ingelheim, InVentiv Health Clinical, Novartis	None	
Mustafa Toma	Novartis, Servier	Merck, Novartis, Servier	None	
Shelley Zieroth	AstraZeneca, Boehringer Ingelheim, Medtronic, Novartis, Servier, St. Jude Medical	Amgen, Bayer, Boehringer Ingelheim, Medtronic, Merck, Novartis, Servier, Tenax Therapeutics	None	

Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this statement.

Member	Consulting Fees/ Honoraria	Clinical Trials	Other Financial Benefit	Relevance to Statement
Secondary Panel				
Kim Anderson	Abbott Canada, Medtronic, Novartis, Servier, Takeda	Amgen, Bayer, Boehringer Ingelheim / Eli Lilly Alliance, Bristol-Myers Squibb, Sanofi, Servier, American Regent	None	These companies produce device and medication used in HF. I received advisory board participation, honoraria for lectures given (developed by myself of CHFS). These are RCT including patients with HF. I am either a local PI or co-PI for these trials.
Sharon A. Bray	None	None	None	
Brian Clarke				
Alain Cohen-Solal	Amgen, Bayer, Boehringer Ingelheim, CVRX, Menarini, Novartis, Pfizer, Roche, Sanofi-Aventis, Servier, Vifor	Amgen, Impulse-Med, MSD, Novartis, Servier, Vifor	None	
Michel D'Astous	AstraZeneca, Bayer, Boehringer Ingelheim, BMS/Pfizer Alliance, Merck, Novartis, Servier	Novartis	None	
Margot Davis	Amgen, Boehringer Ingelheim / Eli Lilly Alliance, Janssen, Novartis, Pfizer, Takeda, Alnylam, Akcea	Pfizer	None	Novartis, BI, Amgen produce drugs used in HF. Pfizer, Alnylam, Akcea make drugs used in the treatment of ATTR cardiomyopathy, a very small part of heart failure management. Pfizer makes tafamidis, used in the treatment of ATTR cardiomyopathy, a very small part of heart failure management.
Sabe De	Bayer, Novartis, Pfizer, Servier	Amgen, AstraZeneca, GE, Novartis, Theracos	None	
Andrew D. M. Grant	None	Amgen, Servier, Cytokinetics	None	I will be the local PI for METEORIC HF, a study of the inotrope Omecamtiv Mecarbil in HFrEF patients. Amgen is the sponsor, in collaboration with Cytokinetics and Servier.
Adam Grzeslo	Novartis	None	None	
Jodi Heshka	Amgen, AstraZeneca, Boehringer Ingelheim / Eli Lilly Alliance, Janssen, Merck, NovoNordisk, Sanofi, Servier	None	None	I have spoken on the evidence behind the use of SGLT2 inhibitors and reduction in hospitalization for heart failure.

Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this statement.

Member	Consulting Fees/ Honoraria	Clinical Trials	Other Financial Benefit	Relevance to Statement
Sabina Keen	None	Novartis	None	I have been asked to be a sub investigator for the Parallax trial but have not recruited anyone as of yet
Simon Kouz	Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Medtronic, Novartis, Pfizer, Sanofi-Aventis, Servier	AstraZeneca, Bayer, Boehringer Ingelheim, BMS/Pfizer Alliance, Bristol-Myers Squibb, DalCor, Eli Lilly, Eisai, Esperion, GlaxoSmithKline, Johnson&Johnson, Merck, Novartis, Pfizer, Sanofi, Servier, Theracos	Amgen, AstraZeneca, Biogen, Boston Scientific, Celgen, Gilead, Medtronic, Johnson & Johnson, Novartis, Roche, Sanofi, Valeant	
Douglas Lee	None	None	None	
Frederick A. Masoudi	None	None	None	
Robert McKelvie	Bayer, Novartis, Pfizer, Servier	Amgen, AstraZeneca, Bayer, Theracos	None	
Marie-Claude Parent	None	Abbott Vascular, Bayer, Merck, Novartis	None	
Stephanie Poon	Boehringer Ingelheim, Novartis	None	None	Have served on national heart failure advisory boards for Novartis and Boehringer Ingelheim
Miroslaw Rajda	Novartis, Otsuka, Pfizer, Roche, Servier	Amgen, Bayer, Novartis, Servier	None	
Abhinav Sharma	BMS Pfizer, Boehringer Ingelheim, Boehringer Ingelheim / Eli Lilly Alliance, Eli Lilly, Medtronic, Merck, Novartis, Roche, Takeda	BMS Pfizer, Boehringer Ingelheim, Boehringer Ingelheim / Eli Lilly Alliance	None	Various molecules have been developed by the companies listed. Clinical trial site.
Kyla Siatecki	None	None	None	
Kate Storm	Novartis, Akcea	None	None	Advisory board meeting on Entresto when first approved in Canada
Bruce Sussex				
Harriette Van Spall	Roche	None	None	
Amelia Ming Ching Yip	Novartis, Servier	Amgen	None	They do not influence me in anyway to using their products. I base my recommendations and clinical practice on evidence-based medicine. I participate in recruiting appropriate patients for the study, which actually is stopping enrollment.